

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following any-grade adverse events was most commonly reported among patients receiving inavolisib in addition to palbociclib/fulvestrant as first-line therapy for early relapse of PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer in the Phase III INAVO-120 trial?
 - Hypotension
 - Dry mouth
 - Bruising
 - Neutropenia
- Which of the following statements best describes the relationship between the duration of prior CDK4/6-inhibitor and progression-free survival (PFS) with elacestrant in the Phase III EMERALD trial for patients with advanced ER-positive, HER2-negative breast cancer who had experienced disease progression on or after endocrine therapy with a CDK4/6 inhibitor?
 - Shorter duration on prior CDK4/6i led to longer PFS with elacestrant
 - Longer duration on prior CDK4/6i led to longer PFS with elacestrant
 - No correlation was reported
- The combination of zanubrutinib/venetoclax/obinutuzumab demonstrated a clinically significant overall response rate of more than 90% in which population of patients on the Phase II BOven trial?
 - Treatment-naïve, TP53 wild-type mantle cell lymphoma (MCL)
 - Treatment-naïve MCL with a TP53 mutation
 - Heavily pretreated, TP53 wild-type MCL
 - Heavily pretreated MCL with a TP53 mutation
- Olaparib in combination with abiraterone and prednisone is FDA approved for patients with metastatic castration-resistant prostate cancer and which of the following mutation statuses?
 - With BRCA mutations
 - With any homologous recombination repair gene mutation
 - Regardless of BRCA mutation status
- Which of the following descriptions best describes TAR-200?
 - Internal radioactive implant
 - Wafer-based chemotherapy implant
 - Intravesical drug delivery system for gemcitabine
 - Alternative electric field therapy
- Which of the following best describes CNS (central nervous system) activity observed with amivantamab with chemotherapy with or without lazertinib for advanced NSCLC with an EGFR mutation after disease progression on osimertinib in the Phase III MARIPOSA-2 trial?
 - Intracranial PFS results suggested no improvement in CNS activity with amivantamab-based therapy relative to chemotherapy alone
 - Intracranial PFS was significantly improved with amivantamab/lazertinib but not amivantamab/chemotherapy
 - Intracranial PFS was significantly improved with both amivantamab-containing arms

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

7. Incidence of which of the following adverse events was significantly reduced with the addition of selinexor to bortezomib/dexamethasone for patients with relapsed/refractory multiple myeloma in the BOSTON trial?
- Cataracts
 - Fatigue
 - Thrombocytopenia
 - Peripheral neuropathy
8. Which of the following outcomes best describes overall survival (OS) with first-line tislelizumab with chemotherapy versus chemotherapy for patients with advanced gastric or gastroesophageal adenocarcinoma in the Phase III RATIONALE-305 study?
- No significant improvement in OS
 - Significant improvement in OS for patients with PD-L1 $\geq 5\%$ only
 - Significant improvement in OS for the intent-to-treat (ITT) population only
 - Significant improvement in OS in both the ITT population and patients with PD-L1 $\geq 5\%$
9. Which of the following toxicity types was most commonly observed in patients receiving ivosidenib for advanced chemotherapy-refractory cholangiocarcinoma with an IDH1 mutation in the Phase III ClarIDHy trial?
- Ocular
 - Gastrointestinal
 - Neurologic
 - Dermatologic
10. Which of the following outcomes was observed in patients who received maintenance olaparib for metastatic pancreatic cancer with a germline BRCA mutation in the Phase III POLO trial?
- No significant improvement in PFS or OS
 - Significant improvement in PFS
 - Significant improvement in OS and PFS